Central nervous system metastases in neuroblastoma

Matthay, Katherine K.; Brisse, H.; Couanet, D.; Couturier, Jérôme; Bénard, Jean; Mosseri, Véronique; Edeline, Véronique; Lumbroso, J.; Valteau‐Couanet, Dominique; Michon, Jean

doi:10.1002/cncr.11448

Cited by 126 publications

(47 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,22) Additionally, N-myc gene amplification has been recognized as a significant risk factor for CNS metastasis. 23) To detect N-myc gene amplification, we employed dual-color FISH using an N-myc probe and a chromosome 2 centromere probe, which was used as an internal control. 16) Deoxyribonucleic acid-based realtime quantitative PCR simultaneously measures N-myc gene and a reference gene, NAGK, which is located on the same chromosome as N-myc, and evaluates N-myc copy number as an N-myc/NAGK ratio.…”

Section: Discussionmentioning

confidence: 99%

“…18) However, lumbar puncture performed at the time of diagnosis is a significant risk factor for the subsequent development of CNS metastasis, so is not recommended for detection of CNS metastasis or to establish a diagnosis. 19,23) The improved survival for patients with neuroblastoma achieved by improved treatments such as chemotherapy, radiotherapy, and surgery may result in increased incidence of CNS metastasis. Metastatic neuroblastoma should be included in the differential diagnosis of hemorrhagic parenchymal brain lesions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Unexpected Intraparenchymal Hematoma Caused by Brain Metastasis in a Patient With Neuroblastoma -Case Report-

Okura

Yatomi

Saito

et al. 2011

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

A 2-year-old girl who had previously been treated for stage IV intra-abdominal neuroblastoma presented with headache and vomiting. Computed tomography (CT) showed hematoma in the right temporal lobe. Two months previously, she had suffered a generalized seizure but brain CT was unremarkable. The hematoma was removed completely without evidence of vascular anomaly or tumor. Four weeks after surgery, magnetic resonance imaging with gadolinium showed a developing mass lesion in the hematoma bed. A second operation for tumor removal confirmed the rare diagnosis of intraparenchymal metastasis. Metastatic neuroblastoma to the central nervous system (CNS) occasionally can cause massive hemorrhage. Therefore, early detection of CNS metastasis can be important. The related factors in this patient with abdominal neuroblastoma included elevated serum lactate dehydrogenase, N-myc gene amplification, and coexisting orbital metastasis, which all occurred within 22 months from initial diagnosis. The median interval from diagnosis of the primary tumor to diagnosis of CNS metastasis in neuroblastoma is 12-22 months, which indicates relatively late metastasis presentation. The initial presentation of this late metastasis is hemorrhage that can have sudden detrimental consequences, so a patient with neuroblastoma must be followed up carefully, particularly if elevated serum lactate dehydrogenase, orbital metastasis, N-myc gene amplification, or clinical symptoms are present, even if brain CT is unremarkable. The understanding that intraparenchymal hematoma can occur prior to detectable CNS metastasis may be important for early detection of this life-threatening condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Unexpected Intraparenchymal Hematoma Caused by Brain Metastasis in a Patient With Neuroblastoma -Case Report-

Okura

Yatomi

Saito

et al. 2011

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

show abstract

“…Depending on the frequency of follow-up and the type of investigations used to monitor relapse, 30 to 73% of patients are asymptomatic at relapse (Kushner et al, 2009;Lau et al, 2004 Table 1. Characteristics of 31 relapsed NB patients from a single institution (Lau et al, 2004) While central nervous system (CNS) disease is very rare at diagnosis, CNS recurrence has been reported in 1 to 5% of all patients with Stage 4 NB (Kellie et al, 1991;Kramer et al, 2001;Matthay et al, 2003a;Shaw & Eden, 1992). CNS metastases represent 6 to 10% of all disease recurrences and 50 to 70% of these CNS recurrences are isolated CNS relapse.…”

Section: Clinical Presentation Of Recurrent Nbmentioning

confidence: 99%

“…Neuroaxis metastases can be intraparenchymal, leptomeningeal, or both. Patients can present with nausea, vomiting, headaches, seizures, drowsiness, cranial nerve symptoms, motor weakness/paralysis, and back pain (Matthay et al, 2003a). Fifty percent of relapses present within 18 months from diagnosis and 77% by 24 months (Kushner et al, 2009;Lau et al, 2004;London & Castel et al, 2011;Santana et al, 2008).…”

Section: Clinical Presentation Of Recurrent Nbmentioning

confidence: 99%

“…Fifty percent of relapses present within 18 months from diagnosis and 77% by 24 months (Kushner et al, 2009;Lau et al, 2004;London & Castel et al, 2011;Santana et al, 2008). For CNS recurrence, the median time of relapse was 12 to 20 months (Kellie et al, 1991;Kramer et al, 2001;Matthay et al, 2003a;Shaw & Eden, 1992). Even though late relapse is uncommon, a small number of patients present with first disease recurrence after 5 years and on rare occasions beyond 10 years from diagnosis.…”

Section: Clinical Presentation Of Recurrent Nbmentioning

confidence: 99%

See 1 more Smart Citation

Recurrent Neuroblastoma

M.S.¹,

Wendy²

2012

Neuroblastoma - Present and Future

View full text Add to dashboard Cite

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Bleeker¹,

Tytgat

Adam

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Neuroblastoma is an embryonic tumour of childhood that originates in the neural crest. It is the second most common extracranial malignant solid tumour of childhood. Neuroblastoma cells have the unique capacity to accumulate Iodine‐123‐metaiodobenzylguanidine (¹²³I‐MIBG), which can be used for imaging the tumour. Moreover, ¹²³I‐MIBG scintigraphy is not only important for the diagnosis of neuroblastoma, but also for staging and localization of skeletal lesions. If these are present, MIBG follow‐up scans are used to assess the patient's response to therapy. However, the sensitivity and specificity of ¹²³I‐MIBG scintigraphy to detect neuroblastoma varies according to the literature. Prognosis, treatment and response to therapy of patients with neuroblastoma are currently based on extension scoring of ¹²³I‐MIBG scans. Due to its clinical use and importance, it is necessary to determine the exact diagnostic accuracy of ¹²³I‐MIBG scintigraphy. In case the tumour is not MIBG avid, fluorine‐18‐fluorodeoxy‐glucose ( 18 F‐FDG) positron emission tomography (PET) is often used and the diagnostic accuracy of this test should also be assessed. Objectives Primary objectives: 1.1 To determine the diagnostic accuracy of ¹²³I‐MIBG (single photon emission computed tomography (SPECT), with or without computed tomography (CT)) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. 1.2 To determine the diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old, i.e. an add‐on test. Secondary objectives: 2.1 To determine the diagnostic accuracy of 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. 2.2 To compare the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) and 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. This was performed within and between included studies. ¹²³I‐MIBG (SPECT‐CT) scintigraphy was the comparator test in this case. Search methods We searched the databases of MEDLINE/PubMed (1945 to 11 September 2012) and EMBASE/Ovid (1980 to 11 September 2012) for potentially relevant articles. Also we checked the reference lists of relevant articles and review articles, scanned conference proceedings and searched for unpublished studies by contacting researchers involved in this area. Selection criteria We included studies of a cross‐sectional design or cases series of prove...

show abstract

Central nervous system metastases in neuroblastoma

Abstract: (Institut Curie) for their support of this project as Chiefs of Pediatric Oncology along with the colleagues and staff in pediatrics at the two institutions for their assistance.

Cited by 126 publications

References 25 publications

Unexpected Intraparenchymal Hematoma Caused by Brain Metastasis in a Patient With Neuroblastoma -Case Report-

Unexpected Intraparenchymal Hematoma Caused by Brain Metastasis in a Patient With Neuroblastoma -Case Report-

Recurrent Neuroblastoma

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Contact Info

Product

Resources

About